Monday June 3 Press Briefing: ASCO Press Releases with links to abstracts

 

Use of Broader Criteria for Clinical Trial Enrollment Would Double Number of Eligible Patients With Lung Cancer

Conclusions: Use of the ASCO-Friends expanded criteria would enable nearly twice as many aNSCLC pts to be considered for trial participation (4,851 patients, 46.2%). Narrower criteria should only be used based on compelling scientific rationale for exclusion.

Original cohort 10,500 (100%)
Traditional exclusions  
Pts excluded for brain mets 2,226 (21.2%)
Pts excluded for prior/concurrent malignancy 2,254 (21.5%)
Pts excluded for CrCl < 60 mL/min 1,509 (14.4%)
Pts excluded by one of 3 traditional criteria 5,005 (47.7%)
Total pts included by traditional criteria 5,495 (52.3%)
Expanded criteria
(Permits brain mets and prior/concurrent malignancy)
 
Pts excluded for CrCl < 30 mL/min 154 (1.5%)
Total pts included by ASCO-Friends criteria 10,346 (98.5%)

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

 

Colorectal Cancer Patients With Liver Metastases Live Just as Long After Laparoscopic Surgery as Open Surgery

The Summary includes updated data, not in the abstract

Conclusions: Laparoscopic surgery in patients with colorectal liver metastases was associated with rates of OS and RFS similar to open surgery. Clinical trial information: NCT01516710

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients With Advanced Urothelial Cancer

 

Conclusions: Preliminary results from this EV pivotal study demonstrated a clinically meaningful ORR, consistent with the phase 1 trial, in la/mUC pts with prior platinum and CPI, including LM pts, where there is a high unmet need. EV was well tolerated with a manageable safety profile in these pts. Updated data, including duration of response, PFS, and OS will be presented. Clinical trial information: NCT03219333

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Over 60 Percent of Gynecologic Oncologists Say They Have Experienced Sexual Harassment

Conclusions: Preliminary results from this EV pivotal study demonstrated a clinically meaningful ORR, consistent with the phase 1 trial, in la/mUC pts with prior platinum and CPI, including LM pts, where there is a high unmet need. EV was well tolerated with a manageable safety profile in these pts. Updated data, including duration of response, PFS, and OS will be presented. Clinical trial information: NCT03219333 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT